For instance, identification of the FLT3 internal tandem duplication mutation in 13–36% of AML (depending on the subgroup)2 has led to the development of the FLT3 inhibitors quizartinib and midostaurin3, the latter of which has recently received FDA approval in combination with standard cytarabine and daunorubicin. This evidence concerns the gene FLT3 and acute myeloid leukemia.